The use of eptacog-α [recombinant factor VIIa] to treat acute intracerebral haemorrhage (ICH) may be highly cost effective in the UK

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1563, 2006-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Eptacog-α not a lifesaver for intracerebral haemorrhage

By  

Inpharma, Vol. 1, Iss. 1639, 2008-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Recombinant Factor VIIa (Eptacog Alfa): A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX

By Lyseng-Williamson Katherine A.   Plosker Greg L.  

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1007-1029

Adis International

Access to resources Recommend Favorite

Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital or Acquired Haemophilia and Other Congenital Bleeding Disorders

By Siddiqui M. Asif A.   Scott Lesley J.  

Drugs, Vol. 65, Iss. 8, 2005-01 ,pp. : 1161-1177

Adis International

Access to resources Recommend Favorite

Eptacog-α: Acute lower limb ischaemia and pulmonary embolism: case report

By  

Reactions Weekly, Vol. 1, Iss. 1330, 2010-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Eptacog alfa [recombinant factor VIIa] reduces perioperative blood loss in patients undergoing retropubic prostatectomy

By  

Inpharma, Vol. 1, Iss. 1371, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite